[go: up one dir, main page]

GR20060100144A - Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene - Google Patents

Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene

Info

Publication number
GR20060100144A
GR20060100144A GR20060100144A GR20060100144A GR20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A GR 20060100144 A GR20060100144 A GR 20060100144A
Authority
GR
Greece
Prior art keywords
genes
pharmaceutical preparations
encapsulation
liposomes
cancer treatment
Prior art date
Application number
GR20060100144A
Other languages
English (en)
Inventor
Original Assignee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by filed Critical
Priority to GR20060100144A priority Critical patent/GR20060100144A/el
Priority to US12/281,541 priority patent/US20090053302A1/en
Priority to BRPI0707059-4A priority patent/BRPI0707059A2/pt
Priority to MX2008011263A priority patent/MX2008011263A/es
Priority to JP2008556861A priority patent/JP2009528340A/ja
Priority to EP07712997A priority patent/EP2001441A2/en
Priority to CA002644566A priority patent/CA2644566A1/en
Priority to RSP-2008/0388A priority patent/RS20080388A/sr
Priority to PCT/GR2007/000015 priority patent/WO2007099377A2/en
Priority to AU2007220263A priority patent/AU2007220263A1/en
Priority to KR1020087024248A priority patent/KR20090023548A/ko
Priority to CNA2007800139281A priority patent/CN101522172A/zh
Priority to EA200801912A priority patent/EA200801912A1/ru
Publication of GR20060100144A publication Critical patent/GR20060100144A/el
Priority to MA31204A priority patent/MA30314B1/fr
Priority to TNP2008000345A priority patent/TNSN08345A1/en
Priority to NO20083927A priority patent/NO20083927L/no
Priority to ZA200807934A priority patent/ZA200807934B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση περιγράφει την οξαλιπλατίνη (oxaliplatin) εγκλεισμένη σε λιποσώματα. Η εν λόγω φαρμακευτική ουσία, είτε σε μονοθεραπεία είτε σε θεραπεία σουνδυσμού με άλλα φαρμακευτικά παρασκευάσματα και αντικαρκινικά γονίδια συνεγκλεισμένα στο λιπόσωμα εγκλεισμού οξαλιπλατίνης, χρησιμοποιείται για τη θανάτωση καρκινικών κυττάρων σε ποικιλία κακοήθων καταστάσεων σε ανθρώπους και ζώα μετά από ενδοφλέβια ένεση. Η εφεύρεση επίσης περιγράφει τον εγκλεισμό περισσοτέρων του ενός διαφορετικών φαρμακευτικών παρασκευασμάτων ή γονιδίων (gene), χρησιμοποιούμενων για την καταπολέμηση καρκινικών κυττάρων, εντός λιποσωμάτων.
GR20060100144A 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene GR20060100144A (el)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GR20060100144A GR20060100144A (el) 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
RSP-2008/0388A RS20080388A (sr) 2006-03-03 2007-03-05 Lečenje malignih bolesti
KR1020087024248A KR20090023548A (ko) 2006-03-03 2007-03-05 암 치료
MX2008011263A MX2008011263A (es) 2006-03-03 2007-03-05 Tratamientos para cancer.
JP2008556861A JP2009528340A (ja) 2006-03-03 2007-03-05 癌治療
EP07712997A EP2001441A2 (en) 2006-03-03 2007-03-05 Cancer treatments
CA002644566A CA2644566A1 (en) 2006-03-03 2007-03-05 Cancer treatments
US12/281,541 US20090053302A1 (en) 2006-03-03 2007-03-05 Cancer treatments
PCT/GR2007/000015 WO2007099377A2 (en) 2006-03-03 2007-03-05 Cancer treatments
AU2007220263A AU2007220263A1 (en) 2006-03-03 2007-03-05 Cancer treatments
BRPI0707059-4A BRPI0707059A2 (pt) 2006-03-03 2007-03-05 método de formação de uma micela que compreende oxaliplatina, método de encapsulação de oxaliplatina em um lipossomo, micela, lipossomo, lipossomo que compreende uma quantidade eficaz de oxaliplatina, uso de um lipossomo, método de tratamento de cáncer e terapia de combinação
CNA2007800139281A CN101522172A (zh) 2006-03-03 2007-03-05 癌症治疗
EA200801912A EA200801912A1 (ru) 2006-03-03 2007-03-05 Лечение рака
MA31204A MA30314B1 (fr) 2006-03-03 2008-09-02 Traitements contre le cancer
TNP2008000345A TNSN08345A1 (en) 2006-03-03 2008-09-03 Cancer treatments
NO20083927A NO20083927L (no) 2006-03-03 2008-09-15 Kreftbehandlinger
ZA200807934A ZA200807934B (en) 2006-03-03 2008-09-16 Cancer treatments

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20060100144A GR20060100144A (el) 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene

Publications (1)

Publication Number Publication Date
GR20060100144A true GR20060100144A (el) 2007-10-17

Family

ID=38325437

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20060100144A GR20060100144A (el) 2006-03-03 2006-03-03 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene

Country Status (17)

Country Link
US (1) US20090053302A1 (el)
EP (1) EP2001441A2 (el)
JP (1) JP2009528340A (el)
KR (1) KR20090023548A (el)
CN (1) CN101522172A (el)
AU (1) AU2007220263A1 (el)
BR (1) BRPI0707059A2 (el)
CA (1) CA2644566A1 (el)
EA (1) EA200801912A1 (el)
GR (1) GR20060100144A (el)
MA (1) MA30314B1 (el)
MX (1) MX2008011263A (el)
NO (1) NO20083927L (el)
RS (1) RS20080388A (el)
TN (1) TNSN08345A1 (el)
WO (1) WO2007099377A2 (el)
ZA (1) ZA200807934B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
KR20080094473A (ko) * 2007-04-20 2008-10-23 한국화학연구원 음이온성 지질나노입자 및 이의 제조방법
CN101969963A (zh) * 2008-01-28 2011-02-09 那野伽利阿株式会社 医药组合物或组合剂
TWI468188B (zh) * 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
CA2753844A1 (en) * 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
EP2123258A1 (en) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
WO2010138550A1 (en) * 2009-05-27 2010-12-02 Northeastern University Conjugated nanodelivery vehicles
WO2011034394A2 (ko) * 2009-09-21 2011-03-24 주식회사 중외제약 옥살리플라틴의 나노 입자 및 이를 제조하는 방법
JP5817053B2 (ja) * 2010-04-02 2015-11-18 国立大学法人 千葉大学 腫瘍特異性を有するリポソーム
CN102133176B (zh) * 2011-03-22 2012-09-05 济南宏瑞创博医药科技开发有限公司 一种奥沙利铂胶束制剂及其制备方法及应用
JP5378469B2 (ja) * 2011-08-11 2013-12-25 学校法人 日本歯科大学 医療用薬剤
EP2883542B1 (en) 2012-08-10 2019-05-01 Taiho Pharmaceutical Co., Ltd. Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
KR20150044838A (ko) * 2012-08-13 2015-04-27 레귤론, 인코퍼레이티드. 리포플라틴을 이용한 암 치료방법
MA37931A1 (fr) * 2012-08-13 2016-07-29 Teni Boulikas Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite
CA2883703C (en) 2012-09-04 2021-10-19 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
EA023757B1 (ru) * 2012-12-24 2016-07-29 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения липосомальной формы оксалиплатина
CA2903234C (en) * 2013-03-13 2018-08-28 Mallinckrodt Llc Liposome oxaliplatin compositions for cancer therapy
AU2014245147B2 (en) * 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
CN103622912B (zh) * 2013-12-05 2016-02-24 常州金远药业制造有限公司 盐酸多柔比星-多西他赛或紫杉醇脂质体制剂及其制备方法
CA2976526A1 (en) * 2015-02-13 2016-08-18 Trendmed Co., Ltd. Compositions and methods of tumor treatment utilizing nanoparticles
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
EP3265059A4 (en) 2015-03-03 2018-08-29 Cureport Inc. Combination liposomal pharmaceutical formulations
KR101687735B1 (ko) * 2015-09-18 2016-12-19 서울대학교 산학협력단 신규의 동결건조보조제 및 새로운 인지질 용해용 혼합용매를 이용한 리포좀 동결분체의 제조방법
US20190307690A1 (en) * 2016-05-03 2019-10-10 The American University In Cairo Liposomal Delivery Systems for Oxaliplatin and in Dual Drug Delivery in Combination with Chemo-sensitizing and Chemo-therapeutic agents
US10940112B2 (en) 2016-05-04 2021-03-09 L.E.A.F. Holdings Group Llc Targeted liposomal gemcitabine compositions and methods thereof
CN106074379B (zh) * 2016-07-11 2019-01-25 中国科学院上海药物研究所 聚乙二醇化奥沙利铂前药及其制备方法和用途
CN112656764B (zh) * 2020-12-28 2022-09-02 吉林大学 一种紫杉醇铂类共载靶向长循环脂质体及应用
CN114814023B (zh) * 2022-04-24 2024-07-30 江苏省中医院 脂质分子在作为胃癌化疗药耐药的预测性标志物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6060080A (en) * 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
CA2046997C (en) * 1990-07-16 2000-12-12 Hiroshi Kikuchi Liposomal products
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
AU2001275423B2 (en) * 2000-06-09 2007-01-11 Regulon, Inc. Encapsulation of polynucleotides and drugs into targeted liposomes
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
JP3415131B1 (ja) * 2002-06-03 2003-06-09 メビオファーム株式会社 リポソーム製剤
BRPI0313191A2 (pt) * 2002-08-02 2016-11-08 Transave Inc composição e processo para produzir um agregado de platina e formulação farmacêutica
WO2004098524A2 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
WO2005000266A2 (en) * 2003-05-22 2005-01-06 Neopharm, Inc. Liposomal formulations comprising a combination of two or more active agents

Also Published As

Publication number Publication date
BRPI0707059A2 (pt) 2011-04-19
MA30314B1 (fr) 2009-04-01
CN101522172A (zh) 2009-09-02
AU2007220263A1 (en) 2007-09-07
NO20083927L (no) 2008-09-15
WO2007099377A3 (en) 2008-04-17
CA2644566A1 (en) 2007-09-07
TNSN08345A1 (en) 2009-12-29
EA200801912A1 (ru) 2009-02-27
JP2009528340A (ja) 2009-08-06
MX2008011263A (es) 2008-12-12
RS20080388A (sr) 2009-07-15
ZA200807934B (en) 2009-11-25
WO2007099377A2 (en) 2007-09-07
KR20090023548A (ko) 2009-03-05
US20090053302A1 (en) 2009-02-26
EP2001441A2 (en) 2008-12-17

Similar Documents

Publication Publication Date Title
GR20060100144A (el) Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
Yingchoncharoen et al. Lipid-based drug delivery systems in cancer therapy: what is available and what is yet to come
Kager et al. Review of mifamurtide in the treatment of patients with osteosarcoma
PT1156789E (pt) Terapia para cancros humanos utilizando cisplatina e outros farmacos ou genes encapsulados em lipossomas
Wu et al. Hyperbaric oxygen potentiates doxil antitumor efficacy by promoting tumor penetration and sensitizing cancer cells
WO2007084670A3 (en) Specific therapy using integrin ligands for treating cancer
MX2007009960A (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
WO2009010287A3 (en) Specific therapy and medicament using integrin ligands for treating cancer
HK1217085A1 (zh) 包封在顆粒中的靶向綴合物及其製劑
MX2007012817A (es) Eliminacion de poblacion celular heterogenea o mezclada en tumores.
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
WO2009091531A3 (en) Uniform-sized, multi-drug carrying and photosensitive liposomes for advance drug delivery
WO2004105782A3 (en) Drug delivery systems for tumor targeting ngr-molecules and uses thereof
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
NZ707377A (en) Combination therapy methods for treating proliferative diseases
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
WO2010136168A3 (en) Continuous administration of cilengitide in cancer treatments
Yan et al. Engineering immunogenic cell death with nanosized drug delivery systems improving cancer immunotherapy
Mulas et al. Current state of the polymeric delivery systems of fluoroquinolones–A review
MX2009006886A (es) Metodo para administracion de doxorubicina liposomal pegilada.
WO2005115360A3 (en) Formulations of anti-pain agents and methods of using the same
WO2014159917A3 (en) Treatment for exposure to nerve agent
WO2007082742A8 (en) Isolated organ perfusion combination therapy of cancer
WO2010057596A3 (en) New therapy and medicament using integrin ligands for treating cancer
WO2009062128A3 (en) Combination drug therapy for the treatment of cancer

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees

Effective date: 20151002